SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
小方
Lv0
0 积分
2021-07-05 加入
最近求助
最近应助
互助留言
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
1天前
已完结
A novel approach to augment single-arm clinical studies with real-world data
5天前
已完结
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
6天前
已完结
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non–small-cell lung cancer (AK104-202 study)
6天前
已完结
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer
6天前
已完结
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
7天前
已完结
A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naïve non-small-cell lung cancer
7天前
已完结
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
7天前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
10天前
已完结
Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial
13天前
已完结
没有进行任何应助
感谢,速度真快
5天前
感谢
6天前
感谢
7天前
谢谢
10天前
非常感谢,帮大忙了
13天前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论